<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03283111</url>
  </required_header>
  <id_info>
    <org_study_id>CSCO-LWP</org_study_id>
    <nct_id>NCT03283111</nct_id>
  </id_info>
  <brief_title>Correlation Analysis of T-lymphocyte Subsets and Prognosis in Autologous Stem Cell Transplantation (ASCT) for Lymphoma</brief_title>
  <official_title>Correlation Analysis of T-lymphocyte Subsets and Prognosis in Autologous Stem Cell Transplantation (ASCT) for Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a retrospective, single-center, non-randomized, non-controlled study. This study aims&#xD;
      to explore the effect of T-lymphocyte subsets changes in immunologic reconstitution and&#xD;
      prognosis in lymphoma patients who were treated by autologous stem cell transplantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      High dose chemotherapy combined with autologous peripheral blood stem cell transplantation is&#xD;
      the consolidation treatment for advanced lymphoma patients and approved for treating&#xD;
      recurrent and refractory lymphoma by prolonging progression-free survival significantly while&#xD;
      also improving quality of life. Evidences to date, have validated that changes of&#xD;
      T-lymphocyte subsets after autologous stem cell transplantation associated closely with&#xD;
      immunologic reconstitution, and have produced amazing effects in prognosis. Whether&#xD;
      T-lymphocyte subsets changes could serve as an effective index for prognosis has been a&#xD;
      serious question for lymphoma patients treated by autologous stem cell transplantation. In&#xD;
      this study, the investigators explore the changes of T-lymphocyte subsets in lymphoma&#xD;
      patients before and after autologous stem cell transplantation, and evaluate the significant&#xD;
      effect of T-lymphocyte subsets changes in immunologic reconstitution and prognosis in these&#xD;
      patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Anticipated">July 2018</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>Progression-free survival serves as an effective index to analysis the correlation of T-lymphocyte subsets and prognosis. And it would be measured within 2 years.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>The investigators would measure the overall survival of participants within 2 years. Overall survival serves as an effective index to analysis the correlation of T-lymphocyte subsets and prognosis.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>autologous stem cell transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lymphoma patients received autologous stem cell transplantation for the first time</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>autologous stem cell transplantation</intervention_name>
    <description>autologous stem cell transplantation</description>
    <arm_group_label>autologous stem cell transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men and women≥18 years, &lt;65 years;&#xD;
&#xD;
          2. Lymphoma patients treated by autologous stem cell transplantation for the first time;&#xD;
&#xD;
          3. ECOG ≤ 2;&#xD;
&#xD;
          4. Ccr ≥ 50 ml/min;&#xD;
&#xD;
          5. ALT, AST and TBIL≤2.5-fold upper normal range;&#xD;
&#xD;
          6. Satisfactory heart and lung function;&#xD;
&#xD;
          7. Women of reproductive potential must have a negative pregnancy test. Male and female&#xD;
             of reproductive potential must agree to practice birth control during the study and&#xD;
             one year post study;&#xD;
&#xD;
          8. Good compliance and sighed informed consent voluntarily.&#xD;
&#xD;
        Patients should be conformed to all inclusion criteria above.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior autologous/ allogeneic hematopoietic stem cell transplantation for lymphoma;&#xD;
&#xD;
          2. Senior or uncontrolled virus injection: HIV, TP, hepatitis virus;&#xD;
&#xD;
          3. Serious complications;&#xD;
&#xD;
          4. LVEF&lt;55%;&#xD;
&#xD;
          5. Atopy or allergy to biological product derived from colibacillus;&#xD;
&#xD;
          6. Women who are breastfeeding, pregnant or refused to practice contraception;&#xD;
&#xD;
          7. Severe mental or nervous system diseases;&#xD;
&#xD;
          8. Severe abnormalities of heart, lung and central nervous system symptoms;&#xD;
&#xD;
          9. Patients with sickle cell disease, erythronoclastic anemia or other hematological&#xD;
             disease which has an impact on medullary hematopoiesis;&#xD;
&#xD;
         10. Enrolled in other study currently or 30 days before screen;&#xD;
&#xD;
         11. Patients, in the opinion of investigators, may not be eligible or are not able to&#xD;
             comply with the study.&#xD;
&#xD;
        Patients conformed to any of above criteria should be excluded from this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Weiping Liu, MD</last_name>
    <phone>8613522796323</phone>
    <email>dreaming2217@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Zhu, MD</last_name>
      <phone>+86-10-88196596</phone>
      <email>zj@bjcancer.org</email>
    </contact>
    <contact_backup>
      <last_name>Weiping Liu, MD</last_name>
      <phone>+86-10-88196109</phone>
      <email>dreaming2217@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jun Zhu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>September 5, 2017</study_first_submitted>
  <study_first_submitted_qc>September 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2017</study_first_posted>
  <last_update_submitted>July 24, 2018</last_update_submitted>
  <last_update_submitted_qc>July 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Jun Zhu</investigator_full_name>
    <investigator_title>Principal Investigator, Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

